

**British Association of Dermatologists
Response to NICE Appraisal Consultation Document
On the Multiple Technology Appraisal (MTA)
Certolizumab pegol and secukinumab for treating active psoriatic arthritis
following inadequate response to disease modifying anti-rheumatic drugs
[ID579].**

**British Association of Dermatologists
Therapy & Guidelines and BADBIR sub-committees**

On behalf of the British Association of Dermatologists, thank you for the opportunity to comment on the Appraisal Consultation Document.

The British Association of Dermatologists have no comments.

**Dr Pamela McHenry
Chair, Therapy & Guidelines sub-committee**